|
|
|
These three pictures currently have the most likes. Good job, Emily! Keep sharing those pictures!
It's not too late to catch up! Send in your entries today, share your pictures to your Facebook Timeline for a chance to win $250! Also, make sure you check the Animal Science Monitor website to view each Photo of the Day from May 15th to May 31st!
Stem Cells to Treat Mastitis?
Mastitis is considered the most expensive disease in the industry. The Dairy Site says it may cost a dairy farmer over $400 and also damages the future output of a cow. This condition is usually treated with antibiotics. However, due to the threat of antimicrobial resistance, researchers are coming up with a new treatment plan.
Daryl Nydam, DVM, PhD, who partners with Van de Walle in this study says that bovine mastitis is the most costly disease in dairy and adds that "The second-most-costly is almost not worth mentioning in comparison."
According to their reports, the secreted factors of these stem cells provide many positive effects. Aside from their role in new blood vessel formation, they also promote cell migration. Both are important to healing damaged tissue caused by mastitis. Read more about the study here.
RICK PASCUAL, CPC/PRC | Recruiter
Rick Pascual recruits in dairy nutrition for feed companies and their supplier s across the United States. Rick joined Continental Search in January 2015 and has successfully filled a number of searches for nutritionists, sales, and sales management for leading companies.
After completing coursework and a grueling exam, Rick became a Certified Personnel Consultant (CPC) in November 2015, as well as a Professional Recruiting Consultant (PRC) by AIRS in April 2016.Visit his LinkedIn profile for more info and to stay updated with news about recent dairy trends.
Vaccinations Up, E Coli Down
E. coli, also known as colibacillosis, is one of the most economically significant and common diseases in poultry all over the world. Poultry Health Today says that new studies make it clear how vaccination helps birds all over the world fight against E. coli.
Studies presented at the 2017 World Veterinary Poultry Association meeting held in Edinburgh showed the impact of the modified-live E. coli vaccine on antibiotic use in broilers. The studies were conducted by Zoetis in both France and Germany.
The researchers in France discovered that E. coli vaccination reduced the total number of antibiotic treatment by 44%. There was also a 40% reduction in antibiotic treatments for colibacillosis. The Germany team conducted the study on 3.3 million broilers in three different farms. They also saw the link between vaccination and the reduction of antibiotic use. You can read the full article here.
Please visit our company website for more poultry industry news. Follow #ContinentalSearch on LinkedIn and Facebook for poultry industry jobs and other employment opportunities in animal health and nutrition.
TRISH VALENZUELA, CPC/PRC | Recruiter
Trish Valenzuela specializes in recruiting for poultry feed additive companies. She has filled positions in technical support, sales, and sales management across the USA.
Trish joined Continental Search in July 2015 and through hard study, she passed two certification programs. She is now a Certified Personnel Consultant (CPC) and a Professional Recruiting Consultant (PRC).
Visit her LinkedIn profile to connect with her and stay updated with current poultry trends. Trish can be reached at (302) 248-8242, through LinkedIn, or at trish@consearch.com.
Zoetis Introduces 2 PCV2 Genotype Protection in a Single Vaccine
The swine industry is going to change forever, thanks to a new vaccine. Pig Health Today reports that the first vaccine with two genotypes of porcine circovirus type 2 (PCV2), 2a and 2b, was announced in San Diego during the American Association of Swine Veterinarians conference.
According to Lucina Galina, DVM, PhD, Zoetis's director of swine technical services, Fostera Gold PCV MH provides a broad range of protection for US swine against evolving PCV2 viruses. A large field trial also showed that it was effective against 2d, which is the most prevalent genotype of the disease.
The comparative field trial involved 880 pigs. This showed how effective it was against genotype 2d. An unvaccinated group served as control while over 300 pigs received the vaccine. After 2 weeks, the pigs were challenged Mycoplasma hyopneumoniae then PCV2d a week later. Viremia was also better controlled in swine that received the vaccine.
The vaccine can be given once in a 2-ml dose at 3 weeks of age or as a split dose 3 weeks apart. The duration of immunity is said to be for at least 23 weeks for PCV and Mycoplasma hyopneumoniae (M. hyo). Presently, its duration of immunity for PCV2 is the longest of any US commercial vaccine of this kind. It also has a high margin of safety.
Are you in the swine industry? If so, I'd like to know what you think of this new vaccine and if it is something you'd like to use on your pigs. Here's a link to the full article for more details.
Come visit our company website for beef industry jobs in your state, industry news, and other animal nutrition updates. Follow #ContinentalSearch on Facebook and LinkedIn for beef jobs in your area and other opportunities in the animal nutrition industry.
ANDY CHATTERJEE | Beef & Swine Recruiting Specialist
Andy Chatterjee is a Talent Scout for Continental Search. He handles placements for the feed industry.  He is currently undergoing training for this demanding position.
Andy was handling operations for Continental Search for four years before he was promoted to Talent Scout. His understanding of the business from the ground up will make him an ideal addition to the recruiting team. You can reach him at (302)-353-4065 ext. 571 or andy@consearch.com.
| Copyright© 2018 Animal Science Monitor, All rights reserved. |
|
